Probiotics and inflammatory bowel disease

Jonkers, Daisy; Stockbrügger, R.W.

doi:10.1258/jrsm.96.4.167

Cited by 22 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New advances in the application of probiotics, are directed to produce significant changes in gut physiology and provide even higher levels of health in humans as well as increase performance parameters in poultry. Current research is still heavily biased toward gastrointestinal applications for probiotics, such as: chronic constipation [54,62,89]; diarrhea [1,16,27,48]; inflammatory bowel disease [27,90]; irritable bowel syndrome [9,91]; and food allergy [92], but the possibilities for impacting many areas of health are numerous. Research has shown that probiotics have potential for human health issues such as: vaginal candidiasis [17,38]; dental caries [93]; allergies [15,26]; autoimmune diseases [26,94,95]; urogenital infections [40]; atopic diseases [92,96]; rheumatoid arthritis [94,97]; and respiratory infections [50].…”

Section: Resultsmentioning

confidence: 99%

Probiotics for Human and Poultry Use in the Control of Gastrointestinal Disease: A Review of Real-World Experiences

Téllez¹,

Rodríguez‐Fragoso²,

Va³

et al. 2013

Altern Integ Med

View full text Add to dashboard Cite

Over a century ago Eli Metchnikoff proposed the revolutionary idea to consume viable bacteria to promote health by modulating the intestinal microflora. The idea is more applicable now than ever, since bacterial antimicrobial resistance has become a serious worldwide problem both in medical and agricultural fields. The interest in digestive physiology and the microbiome has generated data whereby well being of all living organisms with a digestive tract can be enhanced and the risk of disease reduced. Given the recent international legislation and domestic consumer pressures to withdraw growth-promoting antibiotics and limit antibiotics available for treatment of bacterial infections, probiotics can offer alternative options. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Current indications are that mechanism of action involves a number of possibilities like rapid activation of innate host immune responses, assisting in the digestion of food materials etc. In this review, we focused on applying probiotic concept to alleviate chronic constipation and idiopathic diarrhea in humans or for specific pathogen reduction and improvement of GIT diseases in poultry.

show abstract

Section: Resultsmentioning

confidence: 99%

Probiotics for Human and Poultry Use in the Control of Gastrointestinal Disease: A Review of Real-World Experiences

Téllez¹,

Rodríguez‐Fragoso²,

Va³

et al. 2013

Altern Integ Med

View full text Add to dashboard Cite

show abstract

“…2,17,18 Probiotics in both CD and UC cases has shown promising results in adults, although there were only few studies performed with placebo-controlled (level of evidence: 1b). 19 Nutritional therapy may be a primary or adjunctive in CD, but is only adjunctive in UC cases. One pediatric clinical trial showed that enteral nutrition may be as effective as corticocteroid in inducing CD remission (level of evidence: 1b).…”

Section: Discussionmentioning

confidence: 99%

Inflammatory bowel disease in Indonesian children

Hegar¹,

Ananta²,

Rini³

2007

View full text Add to dashboard Cite

“…The probiotic strain was found as effective as the standard therapy mesalazine to keep patients in remission. Since then, probiotics have been mentioned in many review papers as promising new therapy for IBD (24)(25)(26) , whereas others were much more sceptical (27) . Nevertheless the number of clinical trials that investigated the efficacy of probiotics in IBD remains relatively limited.…”

Section: Probiotics In Inflammatory Bowel Diseasesmentioning

confidence: 99%

Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?

2014

View full text Add to dashboard Cite

Crohn's disease (CD) and ulcerative colitis (UC) are the two major phenotypes of inflammatory bowel diseases (IBD) which constitute a spectrum of chronic, debilitating diseases characterised by a relapsing inflammation of the intestinal mucosal lining. Evidence from a variety of disciplines implicates the intestinal microbiota in the pathogenesis of idiopathic IBD and their complications, including pouchitis. Many studies have reported a dysbiosis in IBD, characterised by a decrease in diversity, a decreased abundance of some dominant commensal members (such as Clostridium IV and XIVa) and an increase in detrimental bacteria (such as sulphate reducing bacteria and Escherichia coli). Therapies such as prebiotics and probiotics aim to selectively manipulate the intestinal microbiota and have been evaluated as an attractive therapeutic option with few side effects. The multispecies product VSL#3 was found effective in preventing and maintaining remission in pouchitis, whereas both VSL#3 and E. coli Nissle were effective in maintaining remission in UC. A more drastic approach to restore the composition of the microbiota and correct the underlying imbalance is a faecal microbiota transplantation (FMT). FMT has been successfully applied to treat patients with even recalcitrant Clostridium difficile infection. Particularly in UC, the majority of studies suggest that FMT may be an effective treatment option although the evidence is still limited. It is anticipated that our increasing knowledge on the composition and function of the intestinal microbiota components will allow in the future for a better selection of highly performing bacteria with specific functions required for specific benefits.

show abstract

Probiotics and inflammatory bowel disease

Cited by 22 publications

References 7 publications

Probiotics for Human and Poultry Use in the Control of Gastrointestinal Disease: A Review of Real-World Experiences

Probiotics for Human and Poultry Use in the Control of Gastrointestinal Disease: A Review of Real-World Experiences

Inflammatory bowel disease in Indonesian children

Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?

Contact Info

Product

Resources

About